A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.04.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Rachel Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Genetic Therapy, Arginase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Neurological Disorders and Stroke, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, National Institutes of Health.
Abstract (Originalsprache)
Arginase deficiency, a rare urea cycle disorder, causes progressive neurological impairment and spastic diplegia. Traditional adeno-associated virus (AAV) gene therapy can prevent disease in murine models but requires high doses associated with potential dose-dependent clinical toxicity and may exhibit waning durability when administered early in life. To enhance potency and persistence, we applied piggyBac-mediated transposition to integrate a functional synthetic copy of the human arginase 1 gene (hARG1) into the genome. A hybrid system was developed using AAV9 to deliver the piggyBac transposon carrying this hARG1 expression cassette, paired with a lipid nanoparticle (LNP) delivering mRNA for the super piggyBac (SPB) transposase. Adult conditional Arg1 knockout mice received the hARG1 transposon AAV and catalytically active or inactive SPB mRNA-LNPs, while a traditional non-integrating AAV served as the control. Following disease induction on day 24, all vehicle-treated mice perished by day 50. Mice treated with catalytically active hybrid vectors at doses of 5 × 1011-1 × 1013 genome copies/kg (gc/kg) survived for 9 months, maintained stable arginine, ammonia, and guanidinoacetic acid, and exhibited normalized ureagenesis. Comparable correction was only observed with traditional AAV at 5 × 1013 gc/kg-100-fold higher. These findings demonstrate that transient LNP-mediated transposase delivery combined with AAV-transposon vectors enables durable hepatic correction and markedly improves the therapeutic index for systemic gene transfer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
- Poseida Therapeutics, San Diego, CA 92121, USA.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich 8032, Switzerland.
- Department of Pediatrics, University of Toronto, Toronto, ON M5G 1X8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5G 1X8, Canada; Research Institute, The Hospital for Sick Children, Toronto,…
- Research Institute, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
Förderung
- National Institute of Neurological Disorders and Stroke
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Institutes of Health
- Citrin Foundation
Zitieren
APA
Xu, R., Diep, T., Singh, K., Bakshi, S., Wu, G. F., Lu, M., Tang, G., Schwerk, J., Sun, Q., Häberle, J., Schulze, A., Tkachyova, I., Poms, M., Jacques, B., Rychak, J., Lee, S. J., & Lipshutz, G. S. (2026). A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.04.045
Vancouver
Xu R, Diep T, Singh K, Bakshi S, Wu GF, Lu M, et al. A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.04.045
BibTeX
@article{Xu2026,
author = {Xu, Rachel and Diep, Taryn and Singh, Kiran and Bakshi, Stuti and Wu, Grace F and Lu, Mimi and Tang, Gloria and Schwerk, Johannes and Sun, Qin and Häberle, Johannes and Schulze, Andreas and Tkachyova, Ilona and Poms, Martin and Jacques, Bonnie and Rychak, Joshua and Lee, Sang Jun and Lipshutz, Gerald S},
title = {A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.04.045}
}
EUVIMED